<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5564">
  <stage>Registered</stage>
  <submitdate>19/08/2010</submitdate>
  <approvaldate>19/08/2010</approvaldate>
  <nctid>NCT01185860</nctid>
  <trial_identification>
    <studytitle>A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1</studytitle>
    <scientifictitle>A Multiple-Dose Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted RO5190591 in Combination With Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2009-012426-36</secondaryid>
    <secondaryid>NP22660</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C, Chronic</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - danoprevir
Treatment: drugs - peginterferon alfa-2a [Pegasys]
Treatment: drugs - placebo
Treatment: drugs - ribavirin
Treatment: drugs - ritonavir

Active Comparator: A - 

Experimental: B - 

Placebo Comparator: C - 


Treatment: drugs: danoprevir
oral doses

Treatment: drugs: peginterferon alfa-2a [Pegasys]
180 mcg sc once weekly

Treatment: drugs: placebo
oral doses

Treatment: drugs: ribavirin
1000-1200mg/day po

Treatment: drugs: ritonavir
oral doses

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability: Adverse events, ECG, laboratory parameters</outcome>
      <timepoint>approximately 3 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics: Cmax, AUC, Cmin, Tmax, Cl, T1/2</outcome>
      <timepoint>Days 3-9</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Antiviral activity: HCV RNA (COBAS Taqman HCV Test)</outcome>
      <timepoint>from baseline to Day 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Viral resistance development</outcome>
      <timepoint>from baseline to Day 17</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effects on cytochrome P450(CYP)2C9 and 3A isozymes</outcome>
      <timepoint>from baseline to Day 17</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virological response in prior null-responders</outcome>
      <timepoint>from baseline to week 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Comparison of pharmacokinetics and antiviral activity between treatment-naïve patients and prior null-responders to standard of care treatment</outcome>
      <timepoint>approximately 3 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adults, 18-65 years of age

          -  Chronic hepatitis C genotype 1

          -  HCV treatment naïve, or without sustained virologic response on prior PEG-INF/RBV
             treatment

          -  Body mass index (BMI) 18 - 35 kg/m2, inclusive; minimum weight 45 kg</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Liver cirrhosis

          -  Decompensated liver disease or impaired liver function

          -  Medical condition associated with chronic liver disease other than chronic hepatitis C

          -  Positive for hepatitis B or HIV infection at screening

          -  History of alcohol consumption exceeding 2 standard drinks per day when averaged over
             the course of a given week</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>59</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the efficacy, safety and tolerability of danoprevir (RO5190591) plus
      ritonavir as compared to danoprevir alone or placebo plus ritonavir in patients with chronic
      hepatitis C genotype 1 receiving Pegasys (peginterferon alfa-2a) and ribavirin. Patients in
      cohorts will be randomized to receive either oral doses of danoprevir, or danoprevir plus
      ritonavir, or placebo plus ritonavir. All patients will receive Pegasys (180mcg sc once
      weekly) plus ribavirin (1000-1200mg/day po), with the option to continue this treatment after
      completion of study drug treatment. Anticipated time on study treatment is up to 12 weeks.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01185860</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>